Trinity Biotech has staved off the threat of being delisted from the Nasdaq after months of a consistently low share price. On Thursday, the Wicklow biotechnology company confirmed that it had returned to compliance under Nasdaq’s listing rules on the Nasdaq Global Select stock exchange. This follows warnings first issued over a year ago when its share value was very low for an extended period of time. It was in November 2023 that the Nasdaq Listing Qualifications Department notified Trinity Biotech that its share value was below the threshold of $15 million (€13.91 million) for too long. The company was…

Special Six Nations offer

Become an annual member today for €200 and receive a free copy of ‘From Rags to Riches; The Irish Men’s Team in the Professional Era’ by Feargal O’Rourke

Subscribe

Cancel at any time.

Are you already a member? .